Sign Out
The chronic co-administration of Salbutamol + Ipratropium with other anticholinergic drugs has not been studied. Therefore, the chronic co-administration of Salbutamol + Ipratropium with other anticholinergic drugs is not recommended.
The use of additional beta-agonists, xanthine derivatives and corticosteroids may enhance the effect of Salbutamol + Ipratropium. The concurrent administration of other beta-mimetics, systemically absorbed anticholinergics and xanthine derivatives may increase the severity of side effects. A potentially serious reduction in effect may occur during concurrent administration of beta-blockers.
Beta2-adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta2-adrenergic agonists may be enhanced.
Inhalation of halogenated hydrocarbon anaesthetics such as halothane, trichloroethylene and enflurane may increase the susceptibility to the cardiovascular effects of beta-agonists.
Continue with Google